Community-Acquired Pneumonia Treatment Guidelines
Initial Treatment
- The Infectious Diseases Society of America recommends combination therapy of a β-lactam plus a macrolide as the preferred regimen for hospitalized patients to ensure coverage of both typical and atypical pathogens 1, 2
- For previously healthy patients with no risk factors, oral amoxicillin is recommended as first-line therapy for outpatient treatment of non-severe community-acquired pneumonia (CAP) 3, 4
- Macrolide monotherapy should only be considered in areas with low pneumococcal resistance rates for outpatient treatment of non-severe CAP 1, 2
Hospitalized Patients
- Two equally effective options are recommended for non-ICU hospitalized patients: a respiratory fluoroquinolone as monotherapy, or a β-lactam plus a macrolide 1, 2
- For penicillin-allergic patients, a respiratory fluoroquinolone is the preferred alternative for non-ICU hospitalized patients 1, 2
- Doxycycline can be used as an alternative to macrolides when combined with a β-lactam for non-ICU hospitalized patients 1, 2
Severe CAP
- Immediate treatment with parenteral antibiotics is essential for ICU patients with severe CAP 3, 4
- The recommended regimen is a β-lactam plus either azithromycin or a respiratory fluoroquinolone for ICU patients with severe CAP 1, 2
- For penicillin-allergic patients with severe CAP, a respiratory fluoroquinolone plus aztreonam is recommended 1, 2
Duration of Therapy
- For non-severe CAP, the recommended duration of therapy is 5-7 days 1, 2
- For severe CAP without an identified pathogen, the recommended duration of therapy is 10 days 3, 4
- Extended treatment (14-21 days) is recommended for Legionella pneumonia 4
Switching from IV to Oral Therapy
- Switch to oral therapy when the patient is hemodynamically stable, clinically improving, afebrile for 24-48 hours, and able to take oral medications 1, 2, 4
- Early switch to oral therapy reduces hospital stay and complications 1, 2